{"id":506480,"date":"2020-09-11T17:28:01","date_gmt":"2020-09-11T17:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506480"},"modified":"2020-09-11T17:28:01","modified_gmt":"2020-09-11T17:28:01","slug":"vitiligo-competitive-assessment-emerging-therapies-and-key-companies-vitiligo-pipeline-insights-report-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vitiligo-competitive-assessment-emerging-therapies-and-key-companies-vitiligo-pipeline-insights-report-2020_506480.html","title":{"rendered":"Vitiligo: Competitive Assessment, Emerging Therapies and Key Companies | Vitiligo Pipeline Insights Report 2020"},"content":{"rendered":"
\"Vitiligo:<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Vitiligo Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.\n<\/div>\n

Vitiligo <\/strong>Overview<\/p>\n

Vitiligo is a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins.<\/p>\n

Researchers have identified several forms of Vitiligo. Generalized Vitiligo<\/strong> (also called non-segmental Vitiligo), which is the most common form, involves loss of pigment (depigmentation) in patches of skin all over the body. Another form called Segmental Vitiligo<\/strong> (also known as unilateral or localized Vitiligo) is associated with smaller patches of depigmented skin that appear on one side of the body in a limited area; this occurs in about 10% of affected individuals.<\/p>\n

View report: https:\/\/www.delveinsight.com\/sample-request\/vitiligo-pipeline-insight<\/a><\/strong><\/p>\n

The localized type is further subdivided into focal, segmental, and mucosal<\/strong> subtypes, while the generalized type is subdivided into acrofacial, vulgaris, and universal<\/strong> subtypes. An overlap of various types can be classified as ‘mixed type’.<\/p>\n

The main symptoms of Vitiligo are flat, white spots, or patches on the skin. Gradually the patches become completely white. Sometimes the center of a patch may be white with pale skin around it.<\/p>\n

“Vitiligo Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vitiligo <\/strong>market. A detailed picture of the Vitiligo <\/strong>pipeline landscape is provided, which includes the disease overview and Vitiligo <\/strong>treatment guidelines. The assessment part of the report embraces in-depth Vitiligo <\/strong>commercial assessment and clinical assessment of the Vitiligo <\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo <\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Vitiligo of <\/strong>pipeline development activities <\/span><\/p>\n

The report provides insights into:<\/p>\n